Special tax poisons Hungary's top pharma firm, Richter posts loss in Q4 2022

Several records were achieved last year, though

Hungary Richter delivers major upside surprise, reports robust Q3 figures

No one expected such a great performance

Hungary’s Richter surprises analysts with record Q2 result (3)

Hungary's Richter performs below expectations in Q1

No new record in sales this quarter

ANALYST VIEW - Erste sharply raises target price for Hungary's Richter

Share price climbs to new all-time high

ANALYST VIEW - Drug of Hungary's Richter could be facing new rival

Jefferies publishes opinion

Hungary Richter Q2 results beat expectations

Vraylar sales skyrockets, revenue rises

ANALYST VIEW - Jefferies reviews Richter 'wonder' drug

Vraylar sequential growth to continue after lockdown

ANALYST VIEW - Jefferies publishes research on Hungary's Richter

Target price, rating remain unchanged

Hungary Richter expected to report sales close to previous record

First quarter turned out well, according to analysts

Richter is a top pick, share price may take off

Management considered overly conservative

Hungary Richter Q3 sales, profit driven by Vraylar sales

Revenue rose 28.2% y/y

Hungary Richter seen reporting record quarterly revenue

Profit expected to jump from low base

Hungary's Richter expects cariprazine to drive growth

Not just in the U.S. but in Europe as well

Hungary Richter wonderdrug to be distributed in Asia

Mitsubishi Tanabe will distribute cariprazine in Thailand and Singapore.

Hungarian drugmaker Richter projects slight growth in sales this year

With a 10% decrease in Russia and 20% in China

Vraylar sales in U.S. boost Richter Q2 result

Revenue rose 8.5% to HUF 120 billion.

Richter expected to post higher revenue, lower profit in Q2

Analysts forecast 30% lower net profit.

Good news for Richter, share price jumps

Green-light by FDA warmly welcomed.

Hungary's Richter to report impressive profit growth for Q1

Earnings report to be released on 10 May.